Related Experiment Video
Updated: Aug 19, 2026
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Susceptibility of 327 clinical isolates to netilmicin
Abstract:
Netilmicin, a semisynthetic derivative of sisomicin, was tested against 327 isolates of Staphylococcus aureus, Pseudomonas aeruginosa and Gram-negative enteric bacilli. Seventy-two per cent of the isolates were inhibited at a concentration of 0.5 microgram netilmicin per ml, and 93% of the isolates were susceptible to 4 microgram per ml or less. The MICs of netilmicin and gentamicin for 24 Providencia and 38 Pseudomonas isolates were compared. The activity of netilmicin closely paralleled that of gentamicin, 46% of the Providencia isolates and 32% of the Pseudomonas isolates not being inhibited by 4 microgram per ml of either drug.
Insights
Netilmicin, a semisynthetic antibiotic, showed significant activity against common bacterial pathogens. Most Staphylococcus aureus, Pseudomonas aeruginosa, and enteric bacilli isolates were susceptible to netilmicin, demonstrating its potential as an effective antimicrobial agent.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Netilmicin is a semisynthetic aminoglycoside antibiotic derived from sisomicin.
- Aminoglycosides are crucial in treating serious bacterial infections, particularly those caused by Gram-negative bacteria.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of netilmicin.
- To compare the efficacy of netilmicin with gentamicin against specific bacterial isolates.
Main Methods:
- Antimicrobial susceptibility testing was performed on 327 bacterial isolates.
- Minimum Inhibitory Concentrations (MICs) of netilmicin and gentamicin were determined for selected isolates.
Main Results:
- 72% of isolates were inhibited by 0.5 µg/mL netilmicin; 93% were susceptible to ≤4 µg/mL.
- Netilmicin demonstrated activity comparable to gentamicin against Providencia and Pseudomonas isolates.
Conclusions:
- Netilmicin exhibits broad-spectrum activity against Staphylococcus aureus, Pseudomonas aeruginosa, and Gram-negative enteric bacilli.
- The findings support netilmicin's potential as a therapeutic option for infections caused by susceptible bacteria.
